{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:18:11Z","timestamp":1789017491376,"version":"build-2803163510"},"reference-count":103,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at relatively low levels in other tissues, making it a suitable target for therapeutic antibodies. Several anti-CD38 therapies have been, or are being, developed for the treatment of MM, including daratumumab and isatuximab (SAR650984), respectively. Studies have shown that anti-CD38 therapies are effective in the treatment of relapsed\/refractory MM and are well tolerated, with infusion reactions being the most common side effects. They can be used as monotherapy or in combination with immunomodulatory agents, such as pomalidomide, or proteasome inhibitors to potentiate their activity. Here we examine isatuximab and several anti-CD38 agents in development that were generated using new antibody engineering techniques and that may lead to more effective CD38 targeting. We also summarize trials assessing these antibodies in MM, other malignancies, and solid organ transplantation. Finally, we propose that further research on the mechanisms of resistance to anti-CD38 therapy and the development of biomarkers and new backbone regimens with CD38 antibodies will be important steps in building more personalized treatment for patients with MM.<\/jats:p>","DOI":"10.3390\/cells8121522","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T10:57:27Z","timestamp":1574765847000},"page":"1522","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab"],"prefix":"10.3390","volume":"8","author":[{"given":"Thomas G.","family":"Martin","sequence":"first","affiliation":[{"name":"Hematology\/Oncology, University of California San Francisco, San Francisco, CA 94143-0324, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Corzo","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Chiron","sequence":"additional","affiliation":[{"name":"Translational and Experimental Medicine, Sanofi Research &amp; Development, 94403 Vitry-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Abbadessa","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Campana","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Solanki","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Meng","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lee","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Wiederschain","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-1233","authenticated-orcid":false,"given":"Chen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Sanofi Oncology, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Rak","sequence":"additional","affiliation":[{"name":"Integrated Drug Discovery, Sanofi Research &amp; Development, 94403 Vitry-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: A (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1182\/blood-2006-12-061812","article-title":"CD38\/CD19: A lipid raft-dependent signaling complex in human B cells","volume":"109","author":"Deaglio","year":"2007","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nsb0394-143","article-title":"The crystal structure of cyclic ADP-ribose","volume":"1","author":"Lee","year":"1994","journal-title":"Nat. Struct. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0021-9258(18)94230-4","article-title":"Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity","volume":"264","author":"Lee","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1074\/jbc.270.5.2152","article-title":"A derivative of NADP mobilizes calcium stores insensitive to inositol trisphosphate and cyclic ADP-ribose","volume":"270","author":"Lee","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"Janmaat","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_9","unstructured":"(2015). Darzalex [Package Insert], Janssen Biotech, Inc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Jakobs","year":"2014","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2119\/2006-00086.Lee","article-title":"Structure and enzymatic functions of human CD38","volume":"12","author":"Lee","year":"2006","journal-title":"Mol. Med."},{"key":"ref_16","unstructured":"Cai, T., Wetzel, M.C., Nicolazzi, C., Vallee, F., Deckert, J., Dumontet, C., Plesa, A., Kannt, A., Mikol, V., and Chiron, M. (2013, January 3\u20137). Preclinical Characterization of SAR650984, a Humanized Anti-CD38 Antibody for the Treatment of Multiple Myeloma. Proceedings of the 14th International Myeloma Workshop (IMW), Kyoto, Japan."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/cells4030520","article-title":"NAD+-metabolizing ectoenzymes in remodeling tumor-host interactions: The human myeloma model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rasche, L., Kortum, K.M., Raab, M.S., and Weinhold, N. (2019). The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051248"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: Prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_30","first-page":"500","article-title":"Real-world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries","volume":"128","author":"Coriu","year":"2018","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","article-title":"Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices","volume":"9","author":"Jagannath","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: Patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2018-155","article-title":"Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Dimopoulos","year":"2018","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2016.34.15_suppl.8005","article-title":"Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed\/refractory multiple myeloma (RRMM)","volume":"34","author":"Richter","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.HS9.0000560780.40516.f9","article-title":"Phase 1\/2 study of isatuximab monotherapy for relapsed and\/or refractory multiple myeloma in Japanese patients: PF623","volume":"3","author":"Iida","year":"2019","journal-title":"HemaSphere"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: Enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"Bakker","year":"2011","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"Bakker","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A Phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Attal, M., Richardson, P.G., Raikumar, S.V., San-Miguel, J.F., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., and Dimopoulos, M.A. (2019). Isatuximab plus pomalidomide and low dose dexamethasone versus pomalidomide and low dose dexamethasone in relapsed and refractory multiple myeloma: A randomized, multicenter, open-label, phase 3 study. Lancet, in press.","DOI":"10.1097\/01.HS9.0000561576.58696.ae"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Future Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2019.37.15_suppl.8004","article-title":"A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"37","author":"Richardson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2018.36.15_suppl.8014","article-title":"Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM)","volume":"36","author":"Chari","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood.V128.22.2111.2111","article-title":"Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma","volume":"128","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"ref_48","first-page":"3160","article-title":"A phase Ib study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCDI) in patients with newly diagnosed multiple myeloma non-eligible for transplantation","volume":"130","author":"Ocio","year":"2017","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2018-99-111244","article-title":"Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant","volume":"132","author":"Ocio","year":"2018","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00277-014-2044-x","article-title":"Flow cytometry CD4+CD26\u2212CD38+ lymphocyte subset in the microenvironment of Hodgkin lymphoma-affected lymph nodes","volume":"93","author":"Gasparetto","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ajh.24571","article-title":"CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?","volume":"92","author":"Zaja","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood.V120.21.3935.3935","article-title":"Daratumumab, a novel human anti-CD38 monoclonal antibody for the treatment of chronic lymphocytic leukemia and B-cell non\u2013Hodgkin lymphoma","volume":"120","author":"Rodriguez","year":"2012","journal-title":"Blood"},{"key":"ref_54","first-page":"2814","article-title":"Daratumumab efficiently targets NK\/T cell lymphoma with high CD38 expression","volume":"130","author":"Mustafa","year":"2017","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V128.22.3018.3018","article-title":"Drug resistance alters CD38 expression and in vitro response to daratumumab in Waldenstrom macroglobulinemia cells","volume":"128","author":"Paulus","year":"2016","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2018.12.013","article-title":"Phase 2 study of daratumumab in relapsed\/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma","volume":"19","author":"Salles","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2018-99-111885","article-title":"Daratumumab monotherapy for patients with relapsed or refractory (R\/R) natural killer\/T-cell lymphoma (NKTCL), nasal type: An open-label, single-arm, multicenter phase 2 study","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JCO.2017.35.7_suppl.79","article-title":"CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1\/PD-L1 axis","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Paiva","year":"2016","journal-title":"Cytometry B Clin. Cytom."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJMe1601379","article-title":"HLA-incompatible kidney transplantation\u2014Worth the risk?","volume":"374","author":"Rostaing","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM196904032801401","article-title":"Significance of the positive crossmatch test in kidney transplantation","volume":"280","author":"Patel","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.smim.2011.08.014","article-title":"The state of therapy for removal of alloantibody producing plasma cells in transplantation","volume":"24","author":"Everly","year":"2012","journal-title":"Semin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1093\/ndt\/gfq502","article-title":"Bortezomib: A new player in pre- and post-transplant desensitization?","volume":"25","author":"Lemy","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: Potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_70","first-page":"1062","article-title":"Daratumumab for treatment of antibody-mediated rejection in a kidney transplant recipient","volume":"19","author":"Jordan","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_72","unstructured":"(2019, November 18). Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX\u00ae (Daratumumab) Subcutaneous Formulation. Available online: https:\/\/www.janssen.com\/janssen-submits-application-us-fda-seeking-approval-new-darzalex-daratumumab-subcutaneous."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2019.37.15_suppl.8005","article-title":"Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA","volume":"37","author":"Mateos","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood.V126.23.3015.3015","article-title":"MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds","volume":"126","author":"Boxhammer","year":"2015","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood.V120.21.4018.4018","article-title":"The activity of MOR202, a fully human anti-CD38 antibody, is complemented by ADCP and is synergistically enhanced by lenalidomide in vitro and in vivo","volume":"120","author":"Endell","year":"2012","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1200\/jco.2011.29.15_suppl.8078","article-title":"Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma","volume":"29","author":"Endell","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8574","DOI":"10.1200\/jco.2015.33.15_suppl.8574","article-title":"A phase I\/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)","volume":"33","author":"Raab","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2016.34.15_suppl.8012","article-title":"MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I\/IIa study","volume":"34","author":"Raab","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_79","unstructured":"(2019, September 27). Takeda R&D Investor Day 2018. Available online: https:\/\/www.takeda.com\/siteassets\/system\/investors\/report\/quarterlyannouncements\/fy2018\/0_full_deck_boston_e.pdf."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4049\/jimmunol.198.Supp.224.20","article-title":"TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion","volume":"198","author":"Smithson","year":"2017","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood-2018-99-112916","article-title":"A single administration of the cytolytic CD38 antibody TAK-079 to healthy subjects: Tolerability, pharmacokinetics and pharmacodynamics","volume":"132","author":"Fedyk","year":"2018","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1158\/1538-7445.AM2019-2966","article-title":"Abstract 2966: Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1182\/blood-2018-99-112554","article-title":"Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients: Two-year update of Castor","volume":"132","author":"Mateos","year":"2018","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2017.35.15_suppl.8006","article-title":"Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status","volume":"35","author":"Weisel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.V126.23.1837.1837","article-title":"Serum proteomic analysis of multiple myeloma subjects treated with daratumumab monotherapy","volume":"126","author":"Casneuf","year":"2015","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Atanackovic, D., Yousef, S., Shorter, C., Tantravahi, S.K., Steinbach, M., Iglesias, F., Sborov, D., Radhakrishnan, S.V., Chiron, M., and Miles, R. (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia, 1\u20135.","DOI":"10.1038\/s41375-019-0536-3"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-018-3546-8","article-title":"Navigating the treatment landscape in multiple myeloma: which combinations to use and when?","volume":"98","author":"Goldschmidt","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI82646","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J. Clin. Invest."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_100","first-page":"1858","article-title":"Nivolumab for treatment of advanced, refractory, high-risk multiple myeloma","volume":"130","author":"Thanendrarajan","year":"2017","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Franssen, L.E., Mutis, T., Lokhorst, H.M., and van de Donk, N.W.C.J. (2019). Immunotherapy in myeloma: How far have we come?. Ther. Adv. Hematol., 10.","DOI":"10.1177\/2040620718822660"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Abramson, H. (2018). Monoclonal antibodies for the treatment of multiple myeloma: An update. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201810.0577.v1"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/12\/1522\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:37:46Z","timestamp":1760189866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/12\/1522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":103,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["cells8121522"],"URL":"https:\/\/doi.org\/10.3390\/cells8121522","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]}}}